ATRX immunohistochemistry can help refine ‘not elsewhere classified’ categorisation for grade II/III gliomas

References

• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 2016;131:803–20.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, WHO classification of tumours of the central nervous system. 4th ed. Lyon, France: IARC; 2007.
   Google Scholar
• Yan H, Parsons DW, Jin GL, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765–73.
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. JCO 2009;27:4150–4.
   PubMed Web of Science ®Google Scholar
• Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 2010;75:1560–6.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. New Engl. J. Med 2015;372:2481–2498.
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1988;90:1473–9.
   Google Scholar
• Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825–30.
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Looijenga LHJ, Langenberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003;97:1276–84.
   PubMed Web of Science ®Google Scholar
• Louis DN, Wesseling P, Paulus W, et al. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). Acta Neuropathol 2018;135:481–4.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012;3:709–22.
   PubMed Web of Science ®Google Scholar
• Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012;3:1194–203.
   PubMed Web of Science ®Google Scholar
• Liu X-Y, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012;124:615–25.
   PubMed Web of Science ®Google Scholar
• Purkait S, Miller CA, Kumar A, Sharma V, Pathak P, Jha P, et al. ATRX in diffuse gliomas with its mosaic/heterogeneous expression in a subset. Brain Pathol 2017;27:138–45. doi:10.1111/bpa.12364.
   PubMed Web of Science ®Google Scholar
• Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129:133–46.
   PubMed Web of Science ®Google Scholar
• Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018a;135:639–42.
   PubMed Web of Science ®Google Scholar
• Setty P, Hammes J, Rothamel T, et al. A pyrosequencing-based assay for the rapid detection of IDH1 mutations in clinical samples. J Mol Diagn 2010;12
   PubMed Web of Science ®Google Scholar
• Song X, Allen RA, Dunn ST, et al. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol 2011;4:651–60.
   PubMed Web of Science ®Google Scholar
• Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009;118:599–601.
   PubMed Web of Science ®Google Scholar
• Capper D, Weissert S, Balss J, et al. Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. Brain Pathol 2010;20:245–54.
   PubMed Web of Science ®Google Scholar
• Laxton RC, Popov S, Doey L, et al. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. Neuro-oncology 2013;15:1635–43.
   PubMed Web of Science ®Google Scholar
• Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 2013;126:443–51.
   PubMed Web of Science ®Google Scholar
• Huse JT, Diamond EL, Wang L, Rosenblum MK. Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”?. Acta Neuropathol 2015;129:151–3.
   PubMed Web of Science ®Google Scholar
• Sahm F, von Deimling A. Farewell to oligoastrocytoma: response to letters. Acta Neuropathol 2015;129:155
   PubMed Web of Science ®Google Scholar
• Wilcox P, Li CCY, Lee M, et al. Oligoastrocytomas: throwing the baby out with the bathwater?. Acta Neuropathol 2015;129:147–9.
   PubMed Web of Science ®Google Scholar